Executive Profiles

Christian Wieszner, CSL Behring UK’s new General Manager, talks about his role and his vision for the company’s UK operation going forward.

Carolynn Johnson talks about changing the diversity, equity and includsion trends among the most progressive companies.

Rafael Pharmaceuticals President and CEO Sanjeev Luther shares insights about the strategy he used to shepherd the company’s main compound, devimistat, from near-failure into Phase III trials.

Imvax CEO John Furey taps into tried-and-true powers of hope and clarity as he moves the clinical stage biotech from single program to platform company.

Open Orphan CEO Cathal Friel talks to Pharm Exec about how the company is distinctive from traditional CROs and its role in the UK’s COVID-19 human challenge study.

aTyr Pharma’s Dr. Sanjay S. Shukla talks about how his background in biostatistics, informatics and medicine is helping him and his team of researchers and scientists develop meaningful new medicines in a novel area of immunobiology, by looking at pathways where other drugs may have failed.

Lorna Meldrum, Vice President, Commercial Operations, International Markets & Pandemic at Seqirus, talks about the challenges of the influenza vaccine market and how COVID-19 has highlighted that preventing ’flu is crucial for public health.

Dr. Shankar Musunuri talks about his 25 years’ experience in biotech about his company Ocugen’s latest mission to develop, manufacture, and commercialize Bharat Biotech’s COVID-19 vaccine, COVAXIN, in the North American market.

Teva CEO Kåre Schultz talks about his long industry experience tackling major strategic and operational challenges, and how he is progressing on his current mission to turn around Teva’s fortunes.

Landmark Bio CEO Ran Zheng talks about the value of collaborating with best-in-class partners.

Mark Gergen, Poseida Therapeutics’ President and Chief Business Officer, outlines his company’s commitment to make single-treatment cures a reality.

David Jimenez, President of Janssen Pulmonary Hypertension, talks about how he is delivering on the company’s mission to support earlier diagnosis of people with pulmonary arterial hypertension (PAH).

With a background in pharma and biotech, ImmunoGen president and CEO Mark Enyedy discusses his dedication to oncology and the lessons he’s learned along the way.

Dr. Randall N. Hyer, SVP Global Medical Affairs at Moderna, talks about the strategies that have helped the company grow from startup to multi-billion-dollar firm in a decade.

Ester Banque, senior vice president and head of Intercontinental Commercial at Bristol Myers Squibb, talks purpose and perseverance—both in her own career journey and her group’s mission to topple barriers to drug access in diverse and hard-to-reach regions.

Milan Kalawadia, Senior Vice President, Head of US Commercial Operations at Dr. Reddy‘s, talks about his 15+ years with the India-headquartered company, maintaining a leading position in the generics industry, and the challenges of doing business during the pandemic.

Insights from AmerisourceBergen EVP and Chief Strategy Officer, Leslie Donato.

GSK‘s President of US Pharmaceuticals, Maya Martinez-Davis, outlines her organization’s evolving diversity and inclusion commitments.

Marcelo Bigal, M.D, Ph.D, President and CEO of Ventus Therapeutics, talks about how technological innovation in the field of small molecule drug development has created new opportunities for pursuing undruggable targets, building on the well-established strengths of small molecule medicines.

Influenced by lessons from the playing field, former rugby athlete James Robinson, today president and CEO of Urovant Sciences, discusses the keys to establishing a high-performing team culture in biopharma—and the end-game wins in treatment gain and patient need.

Newly appointed General Manager (UK) at Global Blood Therapeutics (GBT), Nigel Nicholls talks about the company’s vision for Europe and the UK and the health inequity faced by the sickle cell disease community.

Harvard Business School Professor Joseph B. Fuller talks about the future prospects for pharma sales forces as they face more restrictions on accessing their target physicians and looming concerns of automation.

Alnylam's new Chief Commercial Officer, Tolga Tanguler, talks about his new role and what he envisions for the company in the next five years.

Building on a lifelong passion for biomedical research, and then its application in policy and health equity as a leader in various interconnected settings, Michelle McMurry-Heath, president and CEO of BIO, is uniquely positioned as a “translator” for science and social advocacy—and speaking stakeholders to action.

Amgen board member and serial CEO Fred Hassan talks about the three levers Fortune 500 C-suites should consider as they position their firms from pilots to enterprise-wide digital transformation.

Annovis Bio's Maria L. Maccecchini, Ph.D., talks about why she, as a scientist and biotech company entrepreneur, became focused on protecting nerve cells in the brain and in the body, as a way to treat neurodegenerative disease.

David Johnson, Global Director Commercial Excellence at ADVANZ PHARMA, talks about the importance of ensuring the continued supply of complex medicines to European hospitals, to enhance access to critical medicines, helping to broaden patient choice and optimize health outcomes.

Early career ‘assist’ ignites calling in data and healthcare disruption.

Learning from others and leading by example provides full-circle success.

Going all-in on accelerating the promise of cell therapy at larger scale.